$BFRI News

Biofrontera (BFRI) Q1 2026 Earnings Transcript

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Benchmark Downgrades Biofrontera to Speculative Buy, Maintains Price Target to $3

Biofrontera Inc (BFRI) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...

Biofrontera Inc. (BFRI) Q1 2026 Earnings Call Transcript

Biofrontera Inc. (NASDAQ:BFRI) Reports Q1 2026 Revenue and EPS Miss, Stock Falls in Pre-Market

Transcript: Biofrontera Q1 2026 Earnings Conference Call

Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update

Biofrontera Q1 EPS $(0.41) Misses $(0.12) Estimate, Sales $10.084M Miss $10.250M Estimate

Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis

Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026

Biofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Biofrontera Q4 EPS $0.48 Beats $0.20 Estimate, Sales $17.100M Beat $16.146M Estimate

Biofrontera Inc. Q4 2025 Earnings Call Summary

Biofrontera (BFRI) Q4 2025 Earnings Transcript

Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

Biofrontera Inc. Reports Positive Phase 2b Results For Acne Vulgaris Treatment Ameluz Photodynamic Therapy